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ABSTRACT
The aim of this study is to determine if higher than the recommended dosing for
pancreatic enzyme replacement therapy (PERT) improves GI symptoms in children with
Cystic fibrosis. Children with CF and exocrine pancreatic insufficiency (EPI) were
categorized into two groups based on PERT dosing: less than 10,000 lipase units/kg/day,
or greater than 10,000 lipase units/kg/day.
Methods:
142 pediatric CF patients from the Nebraska Regional CF Center were included in the
retrospective evaluation. Patients were split into two different groups based on their
pancreatic enzyme dosing. Group 1 was greater than 10,000 lipase units/kg/day of
enzymes, and group 2 was less than 10,000 lipase units/kg/day.
Results:
The p-value of the results was 0.5992, meaning that there was no statistical difference
between the GI symptoms for those who take less or greater than 10,000 lipase
units/kg/day of enzymes. The group that takes greater than 10,000 lipase units/kg/day
are 1.194 times more likely to experience GI symptoms compared to the group with less
than 10,000 lipase units per day.
Conclusion:
Based on the analysis that was completed on the data, there is no statistical significance
between those that take greater or less than 10,000 lipase units/kg/day of pancreatic
enzymes.

BACKGROUND
Cystic fibrosis (CF) is a genetic disease caused by a defect in the CFTR
gene on chromosome seven3. Complications that may occur from Cystic
fibrosis are asthma, Cystic fibrosis-Related Diabetes (CFRD), sinusitis and
liver disease, among others3. Patients may experience impaired lung
function, pancreatic insufficiency, and gastrointestinal problems3.
Pancreatic enzyme replacement therapy (PERT) is the treatment for
those who are pancreatic insufficient4. About 85% of those with Cystic
fibrosis have pancreatic insufficiency4. Pancreatic insufficiency infers that
a patient does not have full function of the pancreas to be able to digest
food properly to turn into nutrients2. This means that patients need to
take a medication called pancreatic enzymes in order to help the
pancreas turn food into nutrients for the body, which is needed for
proper growth2. Patients need to take a specific dosage per meal
depending on their age, weight, amount of fat in the meal, and
gastrointestinal symptoms to keep their body healthy2. Enzyme
management is very important so that patients do not have side effects
of malabsorption, such as poor weight gain, or gastrointestinal
symptoms, such as increased frequencies of stools, oily stools and/or
floating stools, foul smelling stools, and loose stools3. A patient should
not exceed 10,000 lipase units per kilogram per day2. Fibrosing
colonopathy is the risk factor associated with dosing higher than the
10,000 lipase units/kg/day1. This dosing avoids the risk associated with
the fibrosing colonopathy, but higher dosing may not lead to fewer
symptoms or a better outcome of their diagnosed CF1.

METHODS

DISCUSSION

A retrospective chart review study was conducted of 142 patients with Cystic fibrosis that
are patients at Children’s Hospital and Medical Center in Omaha, NE. Patients between the
ages of 0 to 21 years were included in the study. Patients that were older than 21 or had
not been seen by a Pulmonologist in over a year were excluded from the study, due to not
having any updated information about their enzyme dosing or GI symptoms. This study
contained two distinct groups: patients that take less than 10,000 lipase units/kg/day of
pancreatic enzymes (group 1), and those that take greater than 10,000 lipase units/kg/day
of pancreatic enzymes (group 2). Their charts were analyzed to see if they had severe GI
symptoms due to their enzyme dosing to help with pancreatic insufficiency. The chart
review and data collection for the study was done by looking at the first CF clinic visit of
2021 and comparing the GI symptoms noted at that visit to the symptoms noted 6 months
prior to that date. Variables looked at in the study included enzyme name and dosage,
lipase units/kg/meal, lipase units/kg/day, proton pump inhibitor (PPI) and dosage, CFTR
modulators, weight for length (WFL) percentile, BMI percentile, and z-scores. Several GI
symptoms including steatorrhea, diarrhea, bloating, abdominal pain, poor weight gain, and
constipation were also analyzed. Data was collected and analyzed in an Excel spreadsheet.

It is very important for patients with Cystic fibrosis to take their medications for them to stay healthy and
avoid hospitalizations, as well as keep internal organs healthy and sufficient so that patients can live their
longest life possible. Cystic fibrosis is a life-shortening genetic disease, and these medications are necessary
to keep patients healthy. Pancreatic enzymes are important for those who have pancreatic insufficiency, so
that they can have the help their pancreas needs in order to digest foods and turn them into nutrients. The
research for this project entailed looking at the patient’s enzyme dose and any noted GI symptoms at that
visit. We then reviewed the chart for the 6 months prior to that visit for any GI symptoms the patient was
having. This was used to determine if patients on higher than the recommended enzyme dosing had more
or fewer GI symptoms than patients on lower enzyme dose. Enzymes are used to help with digesting foods
and helping the pancreas turn the food into nutrients, so enzymes and GI symptoms are correlated. The
null hypothesis of this study is there is no difference of GI symptoms between the group with less than
10,000 lipase units/kg/day and the group with greater than 10,000 lipase units/kg/day.
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RESULTS

After the data was analyzed, it was determined that 45.6% of patients who take less than 10,000 units of
enzymes per day experience GI symptoms, while 26.1% of those who take greater than 10,000 units of
enzymes per day experience symptoms. There are 37 patients who take greater than 10,000 units a day
that have symptoms, and 31 of those with less than 10,000 units that experience GI effects. The data
analysis concluded that the p value for the study was 0.5992, meaning that there was no statistical
difference between those who take less or greater than 10,000 units per day of enzymes. The odds ratio
was calculated to be 1.194. Although this is not statistically significant, the group with greater than 10,000
lipase units/kg/day of enzymes was 1.194 more likely to experience GI symptoms compared to the group
with less than 10,000 lipase units/kg/day.
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CONCLUSION
Pancreatic enzymes are very important for patients with pancreatic insufficiency. The
data that was collected in this study was important for determining how many units of
enzymes each patient takes per day and if their dosage correlates with their GI
symptoms. The null hypothesis of this study was accepted, and there was no statistical
significance found between the two groups. Based on these results, it can be concluded
that one group did not experience a significant difference in GI symptoms compared to
the other. If a future study were to be conducted, it can be suggested that more
samples should be used to examine further GI symptom relationships.
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